Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis.

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this meta-analysis publication.

Craniopharyngiomas (CPs) often lead to growth hormone deficiency (GHD) in children.

Growth hormone replacement therapy (GHRT) is essential for managing GHD but its impact on body mass index (BMI) and metabolic outcomes is controversial.

Concerns exist that GHRT might contribute to tumor recurrence, with guidelines varying on when to start therapy post-surgery.

Who the Included Studies Covered

The age groups tagged for this paper are children.

Included studies compared the effects of GHRT in childhood-onset craniopharyngioma patients who received GHRT versus those who did not.

How the Review Was Done

The researchers systematically searched PubMed, Embase, and Cochrane Library databases.

Random-effects meta-analyses were used to pool relative risk (RR) or mean difference (MD) for each outcome.

Heterogeneity was assessed using the I² statistic.

This study is registered with PROSPERO (CRD42024498082).

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Craniopharyngioma, Hormone Replacement Therapy, Human Growth Hormone and Pituitary Neoplasms.

Author keywords: Childhood-onset craniopharyngioma, Growth hormone deficiency, Growth hormone safety, Intracranial tumors, Pediatrics and Tumor progression.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Pituitary), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.